Patents by Inventor Bruce L Roberts
Bruce L Roberts has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11945874Abstract: The present invention relates to humanized immunoglobulins, mouse monoclonal antibodies and chimeric antibodies that have binding specificity for human CD52. The present invention further relates to a humanized immunoglobulin light chain and a humanized immunoglobulin heavy chain. The invention also relates to isolated nucleic acids, recombinant vectors and host cells that comprise a sequence which encodes a humanized immunoglobulin or immunoglobulin light chain or heavy chain, and to a method of preparing a humanized immunoglobulin. The humanized immunoglobulins can be used in therapeutic applications to treat, for example, autoimmune disease, cancer, non-Hodgkin's lymphoma, multiple sclerosis and chronic lymphocytic leukemia.Type: GrantFiled: March 3, 2021Date of Patent: April 2, 2024Assignee: Genzyme CorporationInventors: Bruce L. Roberts, Srinivas Shankara, William Harold Brondyk, William M. Siders
-
Publication number: 20220010024Abstract: The present invention relates to humanized immunoglobulins, mouse monoclonal antibodies and chimeric antibodies that have binding specificity for human CD52. The present invention further relates to a humanized immunoglobulin light chain and a humanized immunoglobulin heavy chain. The invention also relates to isolated nucleic acids, recombinant vectors and host cells that comprise a sequence which encodes a humanized immunoglobulin or immunoglobulin light chain or heavy chain, and to a method of preparing a humanized immunoglobulin. The humanized immunoglobulins can be used in therapeutic applications to treat, for example, autoimmune disease, cancer, non-Hodgkin's lymphoma, multiple sclerosis and chronic lymphocytic leukemia.Type: ApplicationFiled: March 3, 2021Publication date: January 13, 2022Applicant: Genzyme CorporationInventors: Bruce L. Roberts, Srinivas Shankara, William Harold Brondyk, William M. Siders
-
Publication number: 20200040091Abstract: The present invention relates to humanized immunoglobulins, mouse monoclonal antibodies and chimeric antibodies that have binding specificity for human CD52. The present invention further relates to a humanized immunoglobulin light chain and a humanized immunoglobulin heavy chain. The invention also relates to isolated nucleic acids, recombinant vectors and host cells that comprise a sequence which encodes a humanized immunoglobulin or immunoglobulin light chain or heavy chain, and to a method of preparing a humanized immunoglobulin. The humanized immunoglobulins can be used in therapeutic applications to treat, for example, autoimmune disease, cancer, non-Hodgkin's lymphoma, multiple sclerosis and chronic lymphocytic leukemia.Type: ApplicationFiled: April 10, 2019Publication date: February 6, 2020Applicant: GENZYME CORPORATIONInventors: Bruce L. Roberts, Srinivas Shankara, William Harold Brondyk, William M. Siders
-
Publication number: 20170369583Abstract: The invention provides methods of treating lupus in a patient with an anti-CD52 antibody. Also includes are methods of increasing infiltration of regulatory T cells to affected sides of the patient's body, methods of reducing urine protein and/or albumin levels and methods of depleting lymphocytes to alleviate lupus symptoms.Type: ApplicationFiled: March 1, 2017Publication date: December 28, 2017Applicant: GENZYME CORPORATIONInventors: Johanne M. Kaplan, Bruce L. Roberts, William M. Siders
-
Patent number: 9617343Abstract: The invention provides methods of treating lupus in a patient with an anti-CD52 antibody. Also includes are methods of increasing infiltration of regulatory T cells to affected sides of the patient's body, methods of reducing urine protein and/or albumin levels and methods of depleting lymphocytes to alleviate lupus symptoms.Type: GrantFiled: May 13, 2010Date of Patent: April 11, 2017Assignee: GENZYME CORPORATIONInventors: Johanne M. Kaplan, Bruce L. Roberts, William M. Siders
-
Publication number: 20160208010Abstract: The present invention relates to humanized immunoglobulins, mouse monoclonal antibodies and chimeric antibodies that have binding specificity for human CD52. The present invention further relates to a humanized immunoglobulin light chain and a humanized immunoglobulin heavy chain. The invention also relates to isolated nucleic acids, recombinant vectors and host cells that comprise a sequence which encodes a humanized immunoglobulin or immunoglobulin light chain or heavy chain, and to a method of preparing a humanized immunoglobulin. The humanized immunoglobulins can be used in therapeutic applications to treat, for example, autoimmune disease, cancer, non-Hodgkin's lymphoma, multiple sclerosis and chronic lymphocytic leukemia.Type: ApplicationFiled: September 24, 2015Publication date: July 21, 2016Inventors: Bruce L. Roberts, Srinivas Shankara, William Harold Brondyk, William M. Siders
-
Publication number: 20150141303Abstract: A binary or ternary surfactant mixture for use in enhanced oil recovery within a reservoir having total dissolved solids greater than approximately 80,000 parts per million (i.e., heavy to extreme brine conditions) includes at least two of a propoxylated/ethoxylated alcohol sulfate, an ethoxylated alcohol sulfate, and a monoalkyl or dialkyl diphenyloxide disulfonate. The surfactant mixture is used without alcohol, which is unnecessary to maintain solution stability and good coalescence rates and thus improves compatibility with polymers added to improve the mobility ratio. During testing, exceptional solution stability, excellent oil recovery capability, and good compatibility was observed with these surfactant blends. The mixtures are effective at concentrations below 1% and as low as 0.1% by weight.Type: ApplicationFiled: November 18, 2014Publication date: May 21, 2015Inventors: Jeffrey H. Harwell, Tzu-Ping Hsu, Bruce L. Roberts, Bor-Jier Shiau, Mahesh Budhathoki, Prapas Lohateeraparp
-
Publication number: 20140341910Abstract: The present invention relates to humanized immunoglobulins, mouse monoclonal antibodies and chimeric antibodies that have binding specificity for human CD52. The present invention further relates to a humanized immunoglobulin light chain and a humanized immunoglobulin heavy chain. The invention also relates to isolated nucleic acids, recombinant vectors and host cells that comprise a sequence which encodes a humanized immunoglobulin or immunoglobulin light chain or heavy chain, and to a method of preparing a humanized immunoglobulin. The humanized immunoglobulins can be used in therapeutic applications to treat, for example, autoimmune disease, cancer, non-Hodgkin's lymphoma, multiple sclerosis and chronic lymphocytic leukemia.Type: ApplicationFiled: November 26, 2013Publication date: November 20, 2014Applicant: GENZYME CORPORATIONInventors: Bruce L. Roberts, Srinivas Shankara, William Harold Brondyk, William M. Siders
-
Patent number: 8617554Abstract: The present invention relates to humanized immunoglobulins, mouse monoclonal antibodies and chimeric antibodies that have binding specificity for human CD52. The present invention further relates to a humanized immunoglobulin light chain and a humanized immunoglobulin heavy chain. The invention also relates to isolated nucleic acids, recombinant vectors and host cells that comprise a sequence which encodes a humanized immunoglobulin or immunoglobulin light chain or heavy chain, and to a method of preparing a humanized immunoglobulin. The humanized immunoglobulins can be used in therapeutic applications to treat, for example, autoimmune disease, cancer, non-Hodgkin's lymphoma, multiple sclerosis and chronic lymphocytic leukemia.Type: GrantFiled: May 13, 2010Date of Patent: December 31, 2013Assignee: Genzyme CorporationInventors: Bruce L Roberts, Srinivas Shankara, William Harold Brondyk, William M Siders
-
Publication number: 20120100152Abstract: The present invention relates to humanized immunoglobulins, mouse monoclonal antibodies and chimeric antibodies that have binding specificity for human CD52. The present invention further relates to a humanized immunoglobulin light chain and a humanized immunoglobulin heavy chain. The invention also relates to isolated nucleic acids, recombinant vectors and host cells that comprise a sequence which encodes a humanized immunoglobulin or immunoglobulin light chain or heavy chain, and to a method of preparing a humanized immunoglobulin. The humanized immunoglobulins can be used in therapeutic applications to treat, for example, autoimmune disease, cancer, non-Hodgkin's lymphoma, multiple sclerosis and chronic lymphocytic leukemia.Type: ApplicationFiled: May 13, 2010Publication date: April 26, 2012Applicant: GENZYME CORPORATIONInventors: Bruce L Roberts, Srinivas Shankara, William Harold Brondyk, William M. Siders
-
Publication number: 20120070408Abstract: The invention provides methods of treating lupus in a patient with an anti-CD52 antibody. Also includes are methods of increasing infiltration of regulatory T cells to affected sides of the patient's body, methods of reducing urine protein and/or albumin levels and methods of depleting lymphocytes to alleviate lupus symptoms.Type: ApplicationFiled: May 13, 2010Publication date: March 22, 2012Applicant: GENZYME CORPORATIONInventors: Johanne M. Kaplan, Bruce L. Roberts, William M. Siders
-
Publication number: 20120058082Abstract: The invention provides methods for improving the efficacy and reducing side effects of anti-CD52 antibody treatment. The methods can be used to treat patients who are in need of immunoregulation such as lymphocyte depletion and patients who have cancer. Also included are compositions useful for these methods.Type: ApplicationFiled: May 13, 2010Publication date: March 8, 2012Applicant: GENZYME CORPORATIONInventors: Johanne M. Kaplan, Bruce L. Roberts, William M. Siders
-
Patent number: 7078383Abstract: Mutants of Kunitz domain 1 (ITI-D1) of human inter-?-trypsin inhibitor (ITI), are useful as inhibitors of human neutrophil elastase. Mutants characterized by one or more of the following substitutions (numbered to correspond to bovine pancreatic trypsin inhibitor, the archetypal Kunitz domain) are of particular interest: (a) Val15 or Ile15, (b) Ala16, (c) Phe18, (d) Pro19, (e) Arg1, (f) Pro2, and/or (g) Phe4.Type: GrantFiled: January 8, 2002Date of Patent: July 18, 2006Assignee: Dyax Corp.Inventors: Arthur C Ley, Sonia K Guterman, William Markland, Rachel B Kent, Bruce L Roberts, Robert C Ladner
-
Publication number: 20030092162Abstract: The present invention provides chimeric adenoviral vectors that preferentially infect a target mammalian cell. Also provided are methods of targeting gene delivery to a specific cell type, treatment of cancer and methods of inducing a specific immune response in a subject. Pharmaceutical compositions are also provided.Type: ApplicationFiled: December 13, 2002Publication date: May 15, 2003Inventors: Srinivas Shankara, Donna Armentano, Bruce L. Roberts
-
Patent number: 6544328Abstract: A process for preparing an improved pigment which is readily dispersible in paints and plastics concentrates is provided. In accordance with the process, a particulate pigment is mixed with water to form a slurry thereof, and a surface active agent is mixed with the slurry so that the pigment therein is coated therewith. A preferred surface active agent is a mixture of ethoxylated sorbitan derivatives, non-ethoxylated mono and diglycerides and ethoxylated mono and diglycerides. After the pigment has been coated with the surface active agent, the coated pigment is dried.Type: GrantFiled: January 26, 2001Date of Patent: April 8, 2003Assignee: Kerr-McGee Chemical LLCInventors: Bruce L. Roberts, Jeffrey D. Elliott, Ronnie L. Hoskins, Bruce R. Palmer
-
Publication number: 20030029358Abstract: A process for preparing an improved pigment which is readily dispersible in paints and plastics concentrates is provided. In accordance with the process, a particulate pigment is mixed with water to form a slurry thereof, and a surface active agent is mixed with the slurry so that the pigment therein is coated therewith. A preferred surface active agent is a mixture of ethoxylated sorbitan derivatives, non-ethoxylated mono and diglycerides and ethoxylated mono and diglycerides. After the pigment has been coated with the surface active agent, the coated pigment is dried.Type: ApplicationFiled: January 26, 2001Publication date: February 13, 2003Inventors: Bruce L. Roberts, Jeffrey D. Elliott, Ronnie L. Hoskins, Bruce R. Palmer
-
Publication number: 20020151515Abstract: This invention provides an isolated population of polynucleotides comprising or corresponding to at least one polynucleotide shown in Table 1 and their respective complements. It also provides a polynucleotide encoding a ligand or antibody or engineered protein that binds to a cell surface protein of an antigen presenting cell and wherein the polynucleotide comprises or corresponds to a polynucleotide shown in Table 1 or its complement. The invention further provides a polynucleotide that encodes a transcription factor and wherein the polynucleotide comprises or corresponds to a polynucleotide shown in Table 1 or its complement.Type: ApplicationFiled: November 5, 2001Publication date: October 17, 2002Inventor: Bruce L. Roberts
-
Publication number: 20020094530Abstract: The present invention provides methods for methods of identifying novel therapeutic polypeptide antigens and epitopes. These methods are designed to select polypeptides that are particularly effective targets for antibody based immunotherapies.Type: ApplicationFiled: September 18, 2001Publication date: July 18, 2002Inventors: Charles A. Nicolette, Bruce L. Roberts
-
Publication number: 20020041868Abstract: The invention is concerned with fusions of dendritic cells and antigen presenting cells. Also provided are methods of making and using these cell fusions, including methods of adoptive immunotherapy. The fusions according to the invention can also be used in methods for antigen discovery.Type: ApplicationFiled: February 12, 2001Publication date: April 11, 2002Inventors: Charles Nicolette, Bruce L. Roberts, Jianlin Gong, Donald Kufe
-
Publication number: 20020018766Abstract: The present invention calls utilized genes differentially expressed in target cells to design vaccines to generate an immune response. Unlike prior art methods that seek to identify antigenic proteins from phenotypic analysis, the subject method applies functional genomics for antigen identification. The method is exemplified herein and therefore provides compositions and methods for inducing an immune response against gp 100 melanoma cells and for inducing an immune response against HER-2+cells. Cancer vaccines and adoptive immunotherapeutic methods to treat and prevent conditions associated with the presence of these cells in a subject also are provided. The methods can be practiced by administering the appropriate gene or cancer vaccine, antibody, protein, polypeptide, antigen-presenting cell or immune effector cell.Type: ApplicationFiled: April 5, 2001Publication date: February 14, 2002Inventors: Bruce L. Roberts, Srinivas Shankara, Charles A. Nicolette